Document is current
Any future updates will be listed below
-
Authors
Imaizumi, Takahiro https://orcid.org/0000-0003-3831-7241
Asada, Shinji
Ono, Hiroki
Kanai, Sumire
Araki, Shin-ichi
-
Funding
Funding for this research was provided by:
Kyowa Hakko Kirin
- License Information
-
More Information
Article History
Received: 24 December 2025
Accepted: 15 March 2026
First Online: 3 April 2026
Declarations
:
: Takahiro Imaizumi received consultation fees from AstraZeneca K.K. and GlaxoSmithKline K.K. and honoraria from Kyowa Kirin Co., Ltd. and Nippon Boehringer Ingelheim Co., Ltd. Shinji Asada, Hiroki Ono, and Sumire Kanai are employees of Kyowa Kirin Co., Ltd. Shin-ichi Araki received grants from Torii Pharmaceutical Co., Ltd. and Zeria Pharmaceutical Co., Ltd., and honoraria from Kyowa Kirin Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corporation, Kowa Company, Ltd., Ono Pharmaceutical Co., Ltd., and Novo Nordisk Pharma Ltd.
: The study protocol received institutional review board approval in Kyowa Kirin Co., Ltd. (approval number: MA2024_007_00). This study was conducted in accordance with the Declaration of Helsinki.
: As this study utilized exclusively anonymized data, the requirement for obtaining informed consent was waived.
